华海药业
(600521)
| 流通市值：271.42亿 | | | 总市值：279.09亿 |
| 流通股本：14.56亿 | | | 总股本：14.97亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,368,563,881.42 | 9,547,425,412.4 | 7,247,654,219.7 | 5,128,307,063.04 |
| 营业收入 | 2,368,563,881.42 | 9,547,425,412.4 | 7,247,654,219.7 | 5,128,307,063.04 |
| 二、营业总成本 | 2,002,446,656.2 | 7,978,739,192.17 | 5,940,775,917.63 | 4,142,622,747.05 |
| 营业成本 | 834,236,299.54 | 3,636,604,438.41 | 2,705,990,778.14 | 1,948,433,858.93 |
| 税金及附加 | 32,446,838.68 | 116,829,397.55 | 85,557,966 | 60,131,004.67 |
| 销售费用 | 515,002,998.6 | 1,678,900,157.74 | 1,349,133,068.97 | 1,007,232,558.46 |
| 管理费用 | 334,379,521.12 | 1,464,239,757.56 | 991,085,356.96 | 651,598,360.07 |
| 研发费用 | 238,907,980.88 | 986,685,361.64 | 687,452,738.14 | 439,957,268.69 |
| 财务费用 | 47,473,017.38 | 95,480,079.27 | 121,556,009.42 | 35,269,696.23 |
| 其中:利息费用 | 56,895,226.12 | 219,800,151.74 | 168,613,812.76 | 113,927,857 |
| 其中:利息收入 | 5,878,004.57 | 53,215,053.51 | 46,413,286.8 | 38,888,319.07 |
| 加:公允价值变动收益 | 13,253,728.51 | -69,493,156.45 | -51,794,785.91 | -67,208,314.63 |
| 加:投资收益 | -8,001,842.97 | -28,719,824.06 | -22,389,423.24 | -14,307,016.13 |
| 资产处置收益 | -14,072.93 | 2,333,721.93 | 25,370.45 | -390,640.63 |
| 资产减值损失(新) | -19,483,656.25 | -122,874,355.27 | -34,678,626.25 | -29,192,853.3 |
| 信用减值损失(新) | -10,774,825.17 | -36,583,575.06 | -10,714,701.59 | -19,604,762.37 |
| 其他收益 | 35,671,966.73 | 157,439,567.77 | 129,626,392.13 | 102,501,014.06 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 376,768,523.14 | 1,470,788,599.09 | 1,316,952,527.66 | 957,481,742.99 |
| 加:营业外收入 | 686,062.23 | 9,954,857.48 | 6,880,190.11 | 6,746,562.28 |
| 减:营业外支出 | 2,442,285.13 | 17,134,981.62 | 12,569,547.63 | 7,802,959.77 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 375,012,300.24 | 1,463,608,474.95 | 1,311,263,170.14 | 956,425,345.5 |
| 减:所得税费用 | 78,972,621.92 | 356,145,358.12 | 274,015,375.43 | 202,075,398.79 |
| 六、净利润 | 296,039,678.32 | 1,107,463,116.83 | 1,037,247,794.71 | 754,349,946.71 |
| 持续经营净利润 | 296,039,678.32 | 1,107,463,116.83 | 1,037,247,794.71 | 754,349,946.71 |
| 归属于母公司股东的净利润 | 297,404,077.75 | 1,118,981,177.61 | 1,031,268,135.45 | 748,566,030.81 |
| 少数股东损益 | -1,364,399.43 | -11,518,060.78 | 5,979,659.26 | 5,783,915.9 |
| (一)基本每股收益 | 0.21 | 0.77 | 0.71 | 0.52 |
| (二)稀释每股收益 | 0.21 | 0.77 | 0.71 | 0.52 |
| 八、其他综合收益 | 739,654.29 | -110,875.97 | -6,120,263.49 | 516,199.63 |
| 归属于母公司股东的其他综合收益 | 727,805.31 | -20,149.96 | -6,128,737.82 | 532,742.2 |
| 九、综合收益总额 | 296,779,332.61 | 1,107,352,240.86 | 1,031,127,531.22 | 754,866,146.34 |
| 归属于母公司股东的综合收益总额 | 298,131,883.06 | 1,118,961,027.65 | 1,025,139,397.63 | 749,098,773.01 |
| 归属于少数股东的综合收益总额 | -1,352,550.45 | -11,608,786.79 | 5,988,133.59 | 5,767,373.33 |
| 公告日期 | 2025-04-30 | 2025-04-30 | 2024-10-31 | 2024-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |